Evaluating Caribou Biosciences: Insights From 4 Financial Analysts
Portfolio Pulse from Benzinga Insights
In the last three months, 4 analysts have published ratings on Caribou Biosciences (NASDAQ:CRBU), with all ratings being bullish. The average 12-month price target is $15.25, down from a previous average of $19.00. Financial metrics indicate challenges, including a -30.64% revenue decline and a net margin of -1697.57%.
July 17, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Caribou Biosciences (NASDAQ:CRBU) has received 4 bullish ratings in the last three months. The average 12-month price target is now $15.25, down from $19.00. Financial metrics show a -30.64% revenue decline and a net margin of -1697.57%.
The bullish ratings from analysts suggest positive sentiment, but the significant drop in the average price target and poor financial metrics indicate mixed signals. The stock may experience volatility as investors digest these conflicting pieces of information.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100